Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05358353
Other study ID # CP-007
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date October 22, 2024

Study information

Verified date January 2024
Source ReFlow Medical, Inc.
Contact Carolyn Mascho
Phone (616) 802-8575
Email cmascho@reflowmedical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent System).


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date October 22, 2024
Est. primary completion date October 22, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Pre-Procedure Inclusion Criteria: 1. Subject willing and able to provide informed consent and able to comply with the study protocol and follow up. Subjects who are unable to sign due to a physical limitation may have a witness, including a family member, sign on their behalf. 2. Life expectancy greater than 1 year in the investigator's opinion. 3. Male or non-pregnant female =18 years of age at time of consent. 4. Subjects must have chronic (greater than 14 days) symptoms of limb ischemia, determined by clinical symptoms of Rutherford class 4-5, rest pain (R 4), and/or minor tissue loss (R5), that in the opinion of the investigator are not amenable to conservative medical therapy and require endovascular intervention for alleviation of symptoms and tissue preservation. 5. For subjects with bilateral disease, planned treatment of the contralateral limb must either be performed greater than or equal to 3 days prior to the index procedure or greater than or equal to 7 days following the index procedure. Angiographic Inclusion Criteria: 1. Stenotic, restenotic, or occlusive lesions located in the infrapopliteal vessels, with target lesion that can be successfully crossed via the true lumen with a guidewire (no subintimal crossing). 2. Iliac, SFA and popliteal inflow lesions can be treated using standard of care during the index procedure or greater than or equal to 3 days prior. Note: 1. Inflow lesions treated intraprocedure must be treated first, prior to consideration of treatment of infrapopliteal lesions. 2. Treatment of in-stent restenosis in inflow treatment is permitted, provided that stents are not fractured or otherwise compromised. 3. Distal embolic protection is strongly encouraged in cases where atherectomy is used. 4. Inflow lesions must have a healthy vessel segment of greater than 30 mm between the study lesion and the treated segment, defined as less than 50% stenosis without aneurysmal segments. 5. Inflow treatment must be successful, prior to treatment of the target lesion, resulting in stenosis less than or equal to 30%, without resulting flow limiting dissection, thrombus, or aneurysm by angiography. 3. Target vessel(s) reconstitute(s) at or above the ankle, with the target treated segment ending at least 10 mm above the ankle joint. Note: 1. If the anterior tibial or posterior tibial arteries are treated, there must be inline flow to the foot. 2. If the peroneal artery is treated, there must be at least one collateral supplying the foot. 3. In all cases, patent runoff (no lesions with greater than 50% stenosis) must be present via the dorsalis pedis and/or plantar arteries 4. Target lesion must be located in the tibial arteries. If vessel sizing remains appropriate, treatment may extend into the distal popliteal (P3) segment. 5. Target vessel reference diameter is measured to be between 2.5 to 4.5 mm in diameter assessed by one of the following methods after successful completion of guidewire crossing of the lesion site: 1. Intravascular Ultrasound (IVUS) (primary) 2. Visual estimate using Angiography (secondary) 6. Target lesion length is less than or equal to 210mm in length. Tandem lesions that are less than or equal to 4 cm should be treated as one lesion. Multiple discrete lesions may be treated provided cumulative length is less than or equal to 210 mm. 7. Successful pre-dilatation of the target lesion defined as resulting in stenosis less than or equal to 50% and/or inner lumen diameter greater than or equal to 2.0 mm in diameter, without resulting flow limiting dissection, thrombus, or aneurysm by angiography prior to the insertion of the Bare Temporary Spur Stent System. 8. Only one limb and one contiguous vessel may be enrolled per subject. If required, a second modality may be used for treatment in the non-target infrapopliteal vessel. Note: 1. Distal embolic protection is strongly recommended in cases using atherectomy. 2. Treatment of the target vessel/lesion may be performed only if treatment of the non-target lesion is successful without resulting flow limiting (Type D or greater) dissection, thrombus, or aneurysm by angiography. 3. Treatment of non-target lesions must be parallel to, and not contiguous with, the target lesion. 9. If pre-screening with duplex ultrasound, angiography, CTA, or MRA has been performed less than or equal to 365 days prior to the procedure, intra-procedure angiography of the aorto-iliac vasculature is not required, however, the femoropopliteal inflow must still be imaged using angiography during the index procedure. 10. Retrograde access (in the infrapopliteal arteries) is permitted for lesion crossing; however, the Bare Temporary Spur Stent System must be deployed from antegrade (above the knee, either ipsilateral or contralateral) access. Pre-procedure Exclusion Criteria: 1. Subject unwilling or unlikely to comply with the 1-year duration of the study in the opinion of the investigator. 2. Subject is pregnant or planning to become pregnant during the course of the trial. 3. Subject has an active systemic infection that is not controlled at the time of the procedure, including septicemia or bacteremia. 4. Subject has osteomyelitis proximal to the phalanges. Osteomyelitis in the digit(s) of the target foot is permitted. 5. Wounds must be confined to the foot below the ankle. Heel wounds are excluded. 6. Planned major (above the ankle) amputation of the target limb. A planned or previous minor (trans metatarsal amputation or digit amputation) is permitted. 7. Recent myocardial infarction or stroke less than 90 days prior to the index procedure. 8. Symptomatic acute heart failure NYHA class III or greater. 9. Impaired renal function (eGFR less than or equal to 25 mL/min) within 30 days of procedure or end stage renal disease on dialysis. 10. Inability to tolerate dual antiplatelet and/or anticoagulation therapy. 11. Known allergies or sensitivities to heparin, antiplatelet drugs, other anticoagulant therapies which could not be substituted, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure. 12. The subject is currently enrolled in another investigational device or drug trial that interferes with the study endpoints. 13. Known allergy to nitinol or nickel. 14. Bypass surgery of the target vessel(s). Prior bypass above the level of the infrapopliteal arteries is permitted. Angiographic Exclusion Criteria 1. Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion. Inflow must also be free of aneurysmal segments. 2. Fractured or otherwise compromised stents in the target vessel or inflow vessel. 3. In-stent restenosis in the target vessel. 4. Previous treatment of inflow lesions performed less than or equal to 7 days prior to the index procedure. 5. Previous treatment of the target vessel less than or equal to 90 days prior to index procedure. 6. Angiographic evidence of thrombus within target limb. 7. Extremely severe calcification that, in the investigator's opinion, would not be amenable to PTA. 8. Type D dissections or greater incurred during CTO crossing (see Appendix I for definitions). 9. Significant (greater than or equal to 50%) stenosis of inflow arteries or unsuccessful treatment of inflow lesions. 10. Distance from access to lesion is too long for a 135 cm working length of the Bare Temporary Spur Stent System catheter.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Bare Temporary Spur Stent System
Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.

Locations

Country Name City State
United States UnityPoint Health Trinity Bettendorf Hospital Bettendorf Iowa
United States Palm Beach Heart and Vascular Boynton Beach Florida
United States Bradenton Cardiology Bradenton Florida
United States Medical University of South Carolina (MUSC) Charleston South Carolina
United States University of Missouri Columbia Missouri
United States Ohio Health Columbus Ohio
United States Vascular Care Connecticut (site) / Vascular Breakthroughs (research support) Darien Connecticut
United States El Paso Cardiology Associates El Paso Texas
United States First Coast Cardiovascular Institute Fleming Island Florida
United States Advanced Heart and Vascular Institute of Hunterdon Flemington New Jersey
United States Advanced Cardiac and Vascular Centers for Amputation Prevention Grand Rapids Michigan
United States Prisma Health Greenville South Carolina
United States St. Bernards Heart and Vascular Jonesboro Arkansas
United States Advanced Vascular Surgery Kalamazoo Michigan
United States Cardiovascular Institute of the South Lafayette Louisiana
United States Arkansas Heart Hospital Little Rock Arkansas
United States Novant Health Heart & Vascular Institute Matthews North Carolina
United States Baptist Hospital of Miami Miami Florida
United States South Miami Hospital Miami Florida
United States Midwest Cardiovascular Institute Naperville Illinois
United States Vanderbilt University Medical Center Nashville Tennessee
United States Ochsner Health New Orleans Louisiana
United States Columbia University Irving Medical Center New York New York
United States Surgical Specialists of Ocala Ocala Florida
United States Texas Tech University Health Sciences Center Odessa Texas
United States Vascular & Interventional Specialist of Orange County Orange California
United States Ansaarie Cardiac & Endovascular Center of Excellence Palatka Florida
United States The Miriam Hospital Providence Rhode Island
United States Eastlake Cardiovascular PC Roseville Michigan
United States Massachusetts General Hospital Somerville Massachusetts
United States Holy Name Medical Center Teaneck New Jersey
United States Vascular Care Group (site) / Vascular Breakthroughs (research support) Wellesley Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
ReFlow Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint: Technical Success of the Bare Temporary Spur Stent Technical Success is defined as <30% residual stenosis in subjects treated with the Bare Temporary Spur Stent System At the end of the Index Procedure
Primary Co-Primary Safety Endpoint: Freedom from the occurrence of major adverse limb events (MALE) Number of participants with freedom from the occurrence of major adverse limb events (MALE) [evaluated at 30 days post procedure] and peri-operative death (POD) [defined as all-cause mortality within 30 days post procedure].
MALE is defined as:
Above-the-ankle amputation of the index limb
Major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving the infrapopliteal arteries.
30 days post procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A